Anixa Biosciences INC 10-Q quarterly reports

Anixa Biosciences reports a net loss of $2.5 million for the second quarter of 2026 while continuing clinical development of its oncology pipeline.

Anixa Biosciences' latest 10-Q filing reveals a significant reduction in net loss and operating expenses, alongside promising clinical progress in its cancer vaccine and CAR-T therapy programs.

Anixa Biosciences, a biotechnology company focused on oncology therapies and vaccines, reported a reduced net loss for the six months ended April 30, 2025, while continuing to advance its CAR-T and breast cancer vaccine clinical programs, despite an increase in cash used in operating activities and a decline in total current assets.

Anixa Biosciences reports its financial results for the first quarter of 2025, highlighting its ongoing efforts in developing cancer vaccines and CAR-T therapeutics.

Anixa Biosciences reported its financial results for the third quarter of 2024, highlighting ongoing clinical trials and research and development activities.

Anixa Biosciences reported its second quarter 2024 results, highlighting progress in its cancer vaccine and therapy programs, while also detailing a new joint development agreement with Cleveland Clinic.

Anixa Biosciences reported its financial results for the first quarter of 2024, highlighting ongoing developments in its cancer vaccine and therapy programs.